Hemochromatosis - Pipeline Review, H1 2017

Hemochromatosis - Pipeline Review, H1 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Hemochromatosis - Pipeline Review, H1 2017, provides an overview of the Hemochromatosis (Genetic Disorders) pipeline landscape.

Hemochromatosis is an iron disorder in which the body simply loads too much iron. Symptoms include joint pain, abdominal pain, fatigue, weakness, diabetes, liver failure and heart failure. Risk factors include family history, alcoholism, taking dietary supplements with iron or vitamin C and history of diabetes, heart disease, or liver disease.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Hemochromatosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hemochromatosis (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hemochromatosis (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemochromatosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Hemochromatosis (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hemochromatosis (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Hemochromatosis (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hemochromatosis (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hemochromatosis (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hemochromatosis (Genetic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hemochromatosis (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hemochromatosis (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hemochromatosis - Overview
Hemochromatosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hemochromatosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hemochromatosis - Companies Involved in Therapeutics Development
Ionis Pharmaceuticals Inc
Protagonist Therapeutics Inc
Silence Therapeutics Plc
Hemochromatosis - Drug Profiles
Antisense RNAi Oligonucleiotide for Hemochromatosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CN-128 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONISTMPRSS-6LRx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NSC-8679 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PTG-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Replace Hepcidin for Iron Overload Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hemochromatosis - Dormant Projects
Hemochromatosis - Product Development Milestones
Featured News & Press Releases
Jul 28, 2016: Protagonist Therapeutics Receives SBIR Funding for the Development of Injectable Hepcidin Mimetics for Treatment of Iron Overload Disorders
Feb 24, 2016: Merganser Biotech Initiates First Clinical Trial
Nov 01, 2011: UCLA scientists design experimental treatment for iron-overload diseases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables


Number of Products under Development for Hemochromatosis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Hemochromatosis - Pipeline by Ionis Pharmaceuticals Inc, H1 2017
Hemochromatosis - Pipeline by Protagonist Therapeutics Inc, H1 2017
Hemochromatosis - Pipeline by Silence Therapeutics Plc, H1 2017
Hemochromatosis - Dormant Projects, H1 2017

List Of Figures


Number of Products under Development for Hemochromatosis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Hemochromatosis - Pipeline Insight, 2021

DelveInsights, Hemochromatosis Pipeline Insight, 2021, report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Hemochromatosis pipeline landscape. It covers the pipeline drug profiles, including clinical and

USD 1500 View Report

Hemochromatosis - Pipeline Review, H2 2019

Hemochromatosis - Pipeline Review, H2 2019latest Pharmaceutical and Healthcare disease pipeline guide Hemochromatosis - Pipeline Review, H2 2019, provides an overview of the Hemochromatosis (Genetic Disorders) pipeline landscape.Hemochromatosis is an

USD 2000 View Report

Natural Killer Cell Therapies - Pipeline Insight, 2021

DelveInsights, Natural Killer Cell Therapies - Pipeline Insight, 2021, report provides comprehensive insights about 100+ companies and 140+ pipeline drugs in Natural Killer Cell Therapies pipeline landscape. It covers the

USD 3000 View Report

Binge-eating disorder - Pipeline Insight, 2021

DelveInsights, Binge-eating disorder - Pipeline Insight, 2021, report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Binge-eating disorder pipeline landscape. It covers the pipeline drug profiles, including

USD 1500 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available